Cellosaurus cell line VOA3993 (CVCL

Cellosaurus VOA3993 (CVCL_VQ42)

[Text version]

Cell line name

VOA3993

Synonyms

VOA-3993

Accession

CVCL_VQ42

Resource Identification Initiative

To cite this cell line use: VOA3993 (RRID:CVCL_VQ42)

Sequence variations

Mutation; HGNC; HGNC:3690; FGFR3; Simple; p.Phe384Leu (c.1150T>C) (F386L); ClinVar=VCV000134404; Zygosity=Heterozygous (PubMed=27822414).
Mutation; HGNC; HGNC:6193; JAK3; Simple; p.Val722Ile (c.2164G>A); ClinVar=VCV000134573; Zygosity=Heterozygous (PubMed=27822414).
Mutation; HGNC; HGNC:7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Heterozygous (PubMed=27822414).

Disease

Low grade ovarian serous adenocarcinoma (NCIt: C105556)

Species of origin

Homo sapiens (Human) (NCBI Taxonomy: 9606)

Originate from same individual

CVCL_V536 ! VOA1056

Sex of cell

Female

Age at sampling

62Y

Category

Cancer cell line

STR profile

Source(s): PubMed=27822414

Markers:

Amelogenin	X
CSF1PO	10,12
D5S818	11,13
D7S820	8,11
D13S317	8,11
D16S539	11,12
D21S11	30,32.2
TH01	6,9
TPOX	11,12
vWA	18

Publications

DOI=10.14288/1.0319145
Dawson A.
Targeted therapy in low-grade serous ovarian carcinoma: characterization of MEK inhibitor response in novel patient-derived cell lines.
Thesis PhD (2016); University of British Columbia; Vancouver; Canada

PubMed=27822414; PMCID=PMC5088288
Fernandez M.L., DiMattia G.E., Dawson A., Bamford S., Anderson S., Hennessy B.T., Anglesio M.S., Shepherd T.G., Salamanca C.M., Hoenisch J., Tinker A., Huntsman D.G., Carey M.S.
Differences in MEK inhibitor efficacy in molecularly characterized low-grade serous ovarian cancer cell lines.
Am. J. Cancer Res. 6:2235-2251(2016)

Cross-references

Cell line databases/resources

cancercelllines; CVCL_VQ42

Encyclopedic resources

Wikidata; Q98134549

Entry history

Entry creation

07-Sep-2018

Last entry update

19-Dec-2024

Version number